These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29757489)

  • 21. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
    N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
    Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
    Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study.
    Bledsoe JR; Woller SC; Stevens SM; Aston V; Patten R; Allen T; Horne BD; Dong L; Lloyd J; Snow G; Madsen T; Fink P; Elliott CG
    Am J Emerg Med; 2021 Mar; 41():80-83. PubMed ID: 33388651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergency Department Patient Satisfaction with Treatment of Low-risk Pulmonary Embolism.
    Simon LE; Iskin HR; Vemula R; Huang J; Rauchwerger AS; Reed ME; Ballard DW; Vinson DR
    West J Emerg Med; 2018 Nov; 19(6):938-946. PubMed ID: 30429925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
    Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
    N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
    Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
    Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
    Kohn CG; Fermann GJ; Peacock WF; Wells PS; Baugh CW; Ashton V; Crivera C; Schein JR; Wildgoose P; Coleman CI
    Curr Med Res Opin; 2017 Sep; 33(9):1697-1703. PubMed ID: 28665208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge.
    Sharifi M; Bay C; Schwartz F; Skrocki L
    Clin Cardiol; 2014 Feb; 37(2):78-82. PubMed ID: 24122947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
    Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW
    Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.
    Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI
    J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323
    [No Abstract]   [Full Text] [Related]  

  • 33. Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience.
    Filopei J; Bondarsky EE; Ehrlich M; Islam M; Bajpayee G; Pang D; Shujaat A; Rowland J; Steiger DJ
    J Thromb Thrombolysis; 2020 Aug; 50(2):399-407. PubMed ID: 31997255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
    Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
    JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rivaroxaban program for acute venous thromboembolism upon ED discharge, with focus on utility of commercially available dose pack.
    Chu A; Limberg J
    Am J Emerg Med; 2017 Dec; 35(12):1910-1914. PubMed ID: 28869100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of discharge follow-up for acute pulmonary embolism: retrospective cohort study.
    Vinson DR; Ballard DW; Huang J; Rauchwerger AS; Reed ME; Mark DG;
    West J Emerg Med; 2015 Jan; 16(1):55-61. PubMed ID: 25671009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.